Evidence map›Paper›PMID 40252917›Full record

ArticleNew biotechnology2025

Site-directed antibodies targeting driver mutations of the KRAS protein.

Xiaofeng Li, Qiana Mendez, Cassandra Chapados, Felicity Acca, Holly Driscoll, Jason Oliveira, Jun Liu, Kezzia Jones, Mary Ferguson, Ryan L Wallace and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in New biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xiaofeng LiAbbratech, 25 Business Park Drive, Suite C, Branford, CT 06405, USA. Electronic address: xli@abbratech.com.
Qiana MendezAbbratech, 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Cassandra ChapadosAbbratech, 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Felicity AccaAbbratech, 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Holly DriscollAbbratech, 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Jason OliveiraAbbratech, 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Jun LiuAbbratech, 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Kezzia JonesAbbratech, 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Mary FergusonAbbratech, 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Ryan L WallaceAviva Systems Biology Corporation, 6370 Nancy Ridge Dr., Suite 104, San Diego, CA 92121, USA.
Sergei BibikovAviva Systems Biology Corporation, 6370 Nancy Ridge Dr., Suite 104, San Diego, CA 92121, USA.
Troy LionbergerAbbratech, 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Kevin J HarveyAviva Systems Biology Corporation, 6370 Nancy Ridge Dr., Suite 104, San Diego, CA 92121, USA.
Michael P WeinerAbbratech, 25 Business Park Drive, Suite C, Branford, CT 06405, USA.
Greg MirandoAbbratech, 25 Business Park Drive, Suite C, Branford, CT 06405, USA.

Funding

A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12DR44GM149009 · NIGMS · PRECISION BIOTOOLS INC · PI Sara T Passos · 2025 to 2026
$2.4M
Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins.R44GM146473 · NIGMS · ABBRATECH, INC. · PI WEINER, MICHAEL P · 2023 to 2024
$2.2M
Structure-guided neutralizing antibodies developed using EpiVolve technologyR44AI177126 · NIAID · ABBRATECH, INC. · PI LI, XIAOFENG · 2023 to 2024
$1.3M
DIRECTED DISCOVERY AND VALIDATION OF ANTI-SPLICE-JUNCTION SITE AbsR44GM156476 · NIGMS · ABBRATECH, INC. · PI MICHAEL P WEINER · 2024 to 2026
$1.1M
T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategyR43GM149009 · NIGMS · ABBRATECH, INC. · PI WEINER, MICHAEL P · 2023 to 2023
$295k
Method for the isolation of antibodies with functional activity against cell surface targetsR43AI167147 · NIAID · ABBRATECH, INC. · PI WEINER, MICHAEL P · 2022 to 2022
$253k
NIAID NIH HHS R43 AI167147NIAID NIH HHS R44 AI177126NIGMS NIH HHS R43 GM149009NIGMS NIH HHS R44 GM146473NIGMS NIH HHS R44 GM149009NIGMS NIH HHS R44 GM156476
6 · The paper itself

Abstract

Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most mutated oncogene in human cancers, found in approximately 30 % of tumors. These mutations primarily consist of single-base missense alterations in codon G12. While extensive efforts have focused on developing allele-specific inhibitors for KRAS mutations, mutation-specific antibodies (Abs) remain largely unexplored, with only a few research-use-only catalog Abs available. In this study, we employed the proprietary Epivolve technology to develop site-directed monoclonal Abs (mAbs) that target KRAS oncogenic driver mutation KRAS G12D. These site-directed mAbs demonstrate high binding affinity, with equilibrium dissociation constants (K

Indexed as

Antibodies, MonoclonalMutationProto-Oncogene Proteins p21(ras)AnimalsCell Line, TumorHumansMutagenesis, Site-DirectedAntibodies, MonoclonalKRAS protein, humanProto-Oncogene Proteins p21(ras)AntibodyEpivolveImmunizationKRASMutation

Identifiers

PMID40252917
PMCPMC13431000

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.